StudyFinder

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

Recruiting

To assess whether there is superiority of overall survival (OS) when enzastaurin rather than placebo is added to the regimen of temozolomide with radiation therapy followed by temozolomide for the treatment of patients with newly diagnosed glioblastoma in DGM1 biomarker-positive patients, regardless of MGMT methylation status.

I'm interested

This study is NOT accepting healthy volunteers

Glioblastoma

Clinics and Surgery Center (CSC)

Elizabeth Neil - neile@umn.edu
Elizabeth Neil
Phase III
STUDY00011956
NCT03776071
See this study on ClinicalTrials.gov

Back